[Newsmp] Verquvo and Retevmo have received approval for their benefit adequacy and passed the Pharmaceutical Benefit Evaluation Committee of the Health Insurance Review and Assessment Service. Breztri Aerosphere and Jivi have been provisionally recognized.
The Health Insurance Review and Assessment Service (HIRA) has released the results of the 5th Pharmaceutical Benefit Evaluation Committee held on May 4.
On the same day, the Pharmaceutical Benefit Evaluation Committee conducted assessments on the appropriateness of insurance coverage for four medications, Breztri Aeroshphere (AstraZeneca Korea), Verquvo Tab. 2.5mg, 5mg, 10mg (Bayer Korea), Jivi 500,1000,2000,3000IU (Bayer Korea), and Retevmo Cap. 40mg and 80mg, which were submitted for reimbursement approval.
As a result of the evaluation, Verquvo has been approved for reimbursement adequacy in chronic heart failure, and Retevmo for three types of cancers (RET fusion-positive non-small cell lung cancer, RET-mutated medullary thyroid cancer, and RET fusion-positive thyroid cancer).
Furthermore, Breztri Aerosphere has been recognized for its appropriateness for coverage in the maintenance therapy of moderate to severe chronic obstructive pulmonary disease, and Jivi for hemophilia A (coagulation factor deficiency congenital factor VIII deficiency) when the evaluated cost is within the acceptable range.
These medications are finally approved for coverage after undergoing the price negotiation process with the National Health Insurance Corporation and deliberation by the Health Insurance Policy Deliberation Committee.
